期刊
BIPOLAR DISORDERS
卷 14, 期 5, 页码 478-487出版社
WILEY
DOI: 10.1111/j.1399-5618.2012.01033.x
关键词
bipolar disorder; glutamate; glutamate plus glutamine (Glx); meta-analysis; proton magnetic resonance spectroscopy
资金
- University of Oeste Paulista (UNOESTE), Presidente Prudente, Sao Paulo, Brazil
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
- Canadian Institutes of Health Research (CIHR)
- UBC Institute of Mental Health/Coast Capital Depression Research Fund
- Canadian Network for Mood and Anxiety Treatments (CANMAT)
- Canadian Psychiatric Association
- AstraZeneca
- Janssen-Ortho
- Bristol-Myers Squibb
- Otsuka
- Biovail
- Canadian Institutes of Health Research
- Canadian Network for Mood and Anxiety Treatments
- Canadian Psychiatric Association Foundation
- Eli Lilly Co.
- Litebook Company
- Lundbeck
- Lundbeck Institute
- Mochida
- Pfizer
- Servier
- St. Jude's Medical
- Takeda
- UBC Institute of Mental Health/Coast Capital Savings
- Forest
- GlaxoSmithKline
- Janssen
- Michael Smith Foundation for Health Research
- Novartis
- Ranbaxy
- Stanley Foundation
Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 2012: 14: 478487. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: Bipolar disorder (BD) is a common and highly disabling disease characterized by substantial cognitive and functional impairment. The exact neurobiological mechanisms underlying the expression of symptoms in this condition remain unknown but there is growing evidence that glutamate might play an important role. Using proton magnetic resonance spectroscopy (1H-MRS), a number of studies have examined brain glutamate/glutamine levels in patients with bipolar disorder, but they have produced conflicting results. The objective of this paper was to conduct a systematic review and meta-analysis of the literature on brain glutamate/glutamine in BD as measured by 1H-MRS. Methods: A Medline search for the period January 1980April 2010 was conducted to identify published studies that used 1H-MRS to measure glutamate + glutamine (Glx), the Glx/creatine (Cr) ratio, glutamate (Glu), or the Glu/Cr ratio in any brain region in adult or child/adolescent patients with BD and healthy subjects. A meta-analysis of the pooled data was conducted. Results: BD patients were found to have increased Glx compared to healthy subjects when all brain areas were combined. This finding remained true in medicated and non-medicated patients, and in frontal brain areas in adults. There was a non-significant trend (p = 0.09) for an increase in whole-brain Glx/Cr and Glu in patients compared with healthy subjects. No significant difference was found in Glu/Cr. Conclusions: The results of this meta-analysis suggest that brain Glx levels are elevated in BD patients and support the idea that glutamate might play an important role in the pathophysiology of BD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据